Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Medical's leukaemia FISH probe gets Chinese approval

This article was originally published in Clinica

Executive Summary

China Medical Technologies' Leukaemia BCR/ABL FISH (fluorescence in situ hybridisation) Probe has been approved by the Chinese state FDA (SFDA). The molecular diagnostic uses DNA probes to detect Philadelphia translocation, a chromosomal abnormality that is associated with chronic myelogenous, acute myelogenous and acute lymphoblastic leukaemias. This abnormality leads to the BCR and ABL genes fusing together to produce a defective protein called bcr-abl. Detecting the abnormality is important for guiding treatment for these different types of leukaemia – for example, Novartis' Gleevec inhibits the bcr-abl protein. Beijing-based China Medical already markets several FISH probes in China, including ones for prenatal abnormalities and cervical cancer, which were approved in January (, January 26 2009).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts